Abstract 1863
Background
The waiting time for cancer diagnosis and treatment could influence patients’ survival. However, in Poland the waiting time is still long. In Poland, medical care is financed by the government and free for patients, but in a situation of long waiting times for diagnostic tests or in cases where it is impossible to obtain some other health services, patients use the private sector. The rationale for this study was to figure out if there are any difficulties in the oncological system and assessment of whether patients have to use the private sector.
Methods
The study was carried out on a group of 384 patients who were being treated for malignant neoplasm in five oncological centers in Poland. A questionnaire was prepared specifically for this study and each patient was interviewed individually. The questionnaire was validated on a group of 20 patients. The measure of compliance was calculated using Cohen’s Kappa coefficient. The study protocol was approved by the Local Ethics Committee. All of the participants had submitted a signed consent form.
Results
202 women and 180 men (2 no data) were analyzed, median age 65 years. 67% of patients declared problems with getting social service and significant differences in getting social service were observed between various regions of Poland (p < 0.001). One third of patients (32%) used private services during the diagnostic process. Patients with higher education showed significantly more frequent problems (p = 0.03). 91% of patients declared difficulties during treatment. Those who showed significantly more frequent problems were: women (p = 0.04), younger patients (p = 0.0015), professionally active (p = 0.025) with higher education (p < 0.001), living in cities (p = 0.016). More than half of patients with higher education (54%) paid for healthcare services in comparison with patients with lower education levels (average 25%) (p < 0.001).
Conclusions
Cancer patients have some difficulties in the oncological system in Poland. The younger people, those with higher education, the professionally active, and those living in cities seem to be more aware of their rights. The proper solution could be to introduce corrections in oncological organization to avoid the need of using private services.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract